Abstract
P2.09-33 A Phase II Trial of Anlotinib Plus Osimertinib in Advanced NSCLC with EGFR T790M Mutation After Failure of Prior EGFR TKIs
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
https://doi.org/10.1016/j.jtho.2023.09.606
Copy DOIJournal: Journal of Thoracic Oncology | Publication Date: Oct 31, 2023 |
P2.09-33 A Phase II Trial of Anlotinib Plus Osimertinib in Advanced NSCLC with EGFR T790M Mutation After Failure of Prior EGFR TKIs
Join us for a 30 min session where you can share your feedback and ask us any queries you have